Organogenesis Holdings Inc. entered into an At-the-Market Sales Agreement with BTIG, LLC and Citizens JMP Securities, LLC on August 6, 2026, authorizing the sale of up to $75,000,000 in Class A common stock from time to time. The company will pay agents a commission of up to 3.0% of gross sales price. This offering is conducted under an effective shelf registration statement filed on August 8, 2024. Organogenesis Holdings Inc. operates in the medical device industry, specializing in regenerative medicine and wound care solutions.

Organogenesis Holdings Inc. reported second quarter 2026 financial results showing a sharp decline in performance. Net revenue fell 58% to $42.8 million from $100.8 million in the prior year period, driven by a 61% drop in Advanced Wound Care sales to $36.1 million and an 18% decrease in Surgical & Sports Medicine revenue to $6.7 million. The company reported a net loss of $96.3 million, or $(0.77) per share, compared to a net loss of $9.4 million, or $(0.10) per share, in the second quarter of 2025. Adjusted EBITDA widened significantly to a loss of $34.4 million from a loss of $3.6 million year-over-year. Management updated its full-year 2026 revenue guidance downward to between $179.0 million and $215.0 million, reflecting slower-than-expected recovery from market contraction. As of June 30, 2026, the company held $46.8 million in cash and had no outstanding debt. Organogenesis Holdings Inc. operates in the regenerative medicine industry, developing and selling product solutions for Advanced Wound Care and Surgical & Sports Medicine markets.